Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment expenses reviewed by the CDMO

The following table provides R&D expenses by program with a reconciliation to net loss for the periods indicated, which are regularly reviewed by the CODM:

	Years Ended December 31,
	2024			2023
	(in thousands)
Collaboration and other revenue	$	11,000		$	—
Program expenses:
Mecbotamab vedotin, BA3011 (CAB AXL-ADC)		12,934			24,533
Ozuriftamab vedotin, BA3021 (CAB ROR2-ADC)		8,962			13,530
Evalstotug, BA3071 (CAB CTLA-4)		9,103			17,099
BA3182 (CAB EpCAM x CAB CD3)		5,111			4,048
Other CAB Programs		6,912			22,159
Total program expenses		43,022			81,369
Personnel and related		12,082			12,552
Equity-based compensation		4,238			5,462
Facilities and other		3,753			4,348
Total research and development expenses		63,095			103,731
General and administrative expenses
Personnel and related		7,213			7,553
Equity-based compensation		4,683			8,082
Facilities and other		9,952			10,321
Total general and administrative expenses		21,848			25,956
Interest and other income/(expense)		4,167			6,225
Net loss and comprehensive loss	$	(69,776	)	$	(123,462	)